Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein levels between breast Cancer Patients
DOI:
https://doi.org/10.54361/ljmr.v14i2.04Keywords:
Erythrocyte Sedimentation Rate, C-Reactive Protein, Breast CancerAbstract
Background: Inflammatory response plays an essential role in the initiation and progression of several cancers, including breast cancer. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are two inflammatory indicators that increase in many pathologic and physiologic conditions. The objectives of this study were to estimate and compare the levels of these inflammatory markers in breast cancer patients with those of apparently healthy subjects without the disease. Methods: This is a case study conducted at the National Cancer Institute, Sabratha Hospital and Medical Research Center in Zawiya, during 2019. The study population includes 80 subjects (30 healthy women and 50 confirmed breast cancer cases). The levels of ESR and CRP were investigated using standardized laboratory methods. Results: The obtained results showed that the ESR levels of the participants with breast cancer were highly significant compared to that of the controls, but there was no significant difference in levels of CRP. The levels of ESR in all stages of BC were statistically significant compared to control individuals. In contrast, no significant difference in CRP in BC patients with stage III and VI and in controls, despite the significant difference in levels of CRP noticed between BC patient with stage II and controls. There were no differences between the levels of ESR in patients with and without chronic diseases. The levels of CRP showed significant differences between patients with chronic diseases and controls. ESR levels remained elevated despite the course of BC treatment and the levels of CRP in patients, who had combination of chemotherapy and radiotherapy, were increased. In conclusion, this study suggests that ESR is significantly raised in breast cancer patients, whereas, there is no association between of CRP and breast cancer
Downloads
References
Mckeown N. Antioxidants and breast cancer (1999). Nutr Rev. 57: 321-324.
F Balkwill, A Mantovani (2001). Inflammation and cancer: back to Virchow? Lancet. 357:539–45.
Ganesh N. Sharma, Rahul Dave, JyotsanaSanadya, Piush Sharma, and K. K Sharma3 (2010). VARIOUS TYPES AND MANAGEMENT OF BREAST CANCER: An Overview.JAdv Pharm Technol Res. 2: 109–126.
Robert Coleman Mills (2017). Breast Cancer Survivors, Common Markers of Inflammation, and Exercise: A Narrative Review. Breast Cancer (Auckl). 11:1178223417743976.
Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM (2012). Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 104;815–840.
Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM (2009). Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J ClinOncol. 27:3437–3444.
Das Roy L, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P (2009). Breast‑cancer‑associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res. 11:R56.
Mantovani A1, Garlanda C, Doni A, Bottazzi B (2007). Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J ClinImmunol. 2008 Jan;28(1):1-13. Epub
Kushner I. Acute phase reactants. UpToDate 2014 Jul 15.
Saadeh C. The erythrocyte sedimentation rate: Old and new clinical applications. South Med J 1998;91:220‑5.
Sox HC Jr., Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986;104:515‑23
Ljungberg B, Grankvist K, Rasmuson T (1995). Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer. 76:1435‑9.
Henry‑Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al (1991). Erythrocyte sedimentation rate predicts early relapse and survival in early‑stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med. 114:361‑5.
Mantovani A, Garlanda C, Doni A, Bottazzi B (2008). Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J ClinImmunol. 1:1-13.
Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C‑reactive protein is associated with incident cancer and survival in patients with cancer. J ClinOncol. 27:2217‑24.
Schmid M, Schneitter A, Hinterberger S, Seeber J, Reinthaller A, Hefler L (2007). Association of elevated C‑reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. ObstetGynecol . 110:1231‑6.
Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA (2007). C‑reactive protein is a prognostic parameter in patients with cervical cancer. GynecolOncol. 107:114‑7.
O’Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R (2010). Elevated preoperative C‑reactive protein predicts poor cancer specific survival in patients undergoing resection for non‑small cell lung cancer. J ThoracOncol. 5:988‑92.
Roxburgh CS, McMillan DC (2010). Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6:149‑63.
Williams MR, Turkes A, Pearson D, Griffiths K, Blamey RW (1990). An objective biochemical assessment of therapeutics response in metastatic breast, a study with external review of clinical data. Br J Cancer. 61:126-132.
ShilpaBalajiAsegaonkar, BalajiNarayanraoAsegaonkar, UnmeshVidyadharTakalkar, Suresh Advani, and AnandPandurangThorat (2015).C-Reactive Protein and Breast Cancer: New Insights from Old Molecule . Int J Breast Cancer. 26;2015:145647.
Eboreime O, Atoe K, Idemudia JO (2015). Erythrocyte Sedimentation Rate and C-Reactive Protein Levels in Breast Cancer Patients in Benin City, Nigeria. IOSR-JDMS. 6: 116-119.
Pagana KD, Pagana TJ, MacDonald S. Mosby's Canadian manual of diagnostic and laboratory tests. Toronto: Mosby Canada; 2013.
Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC, (2006). Evaluation of an inflammation‑based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 94:227‑30.
Abuquerque KV, Price MR, Badley RA, Jonup I, Pearson D, Blamey RW, (1995). Pretreatment serum level of tumour makers in metastatic breast cancer; a prospective assessment of their role in predicting response to therapy and survival. Eur J SurgOncol. 24;504-9.
Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H (1987). Interferon beta 2/B‑cell stimulatory factor type 2 shares identity with monocyte‑derived hepatocyte‑stimulating factor and regulates the major acute phase protein response in Liver Cells. ProcNatlAcadSci U S A. 20 :7251-7255.
Tennant F (2013). Erythrocyte sedimentation rate and C-reactive protein: old but useful biomarkers for pain treatment. Pract Pain Manage. 2:61-65
ShilpaBalajiAsegaonkar, UnmeshVidyadharTakalkar , PushpaKodlikeri , AvinashPagdhune , VirendrakumarBonduliya , AnandPandurangThorat (2014). Serum high sensitivity C-reactive protein in breast cancer patients. Int J Res Med Sci. 4:1408-1411.
O'Hanlon,D.M., Lynch,J., Cormican,M., &Given,H.F. (2002) The acute phase response in breast carcinoma. Anticancer Res. 22, 1289-1293
University of South Australia (2018). Higher risk of chronic diseases later in life for women with breast cancer. https://www.unisa.edu.au/Media-Centre/Releases/2018/Hormone-treatment-for-breast-cancer-linked-to-chronic-disease-later-in-life/
Grace Sun, Sangeeta R Kashyap (2011). Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations. J NutrMetab. 708183.
Jeong H, Baek S-Y, Kim SW, et al (2019). C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey. BMJ Open;9:e029861. doi:10.1136/ bmjopen-2019-029861.
Kirsten Erickson, Ruth E. Patterson, Shirley W. Flatt, Loki Natarajan, Barbara A. Parker, Dennis D. Heath,Gail A. Laughlin, NazmusSaquib, Cheryl L. Rock, and John P. Pierce (2011). Clinically Defined Type 2 Diabetes Mellitus and Prognosis in Early-Stage Breast Cancer. J ClinOncol. 1: 54–60.
Mukherjee D, Coates PJ, Lorimore SA, Wright EG (2014). Responses to ionizing radiation mediated by inflammatory mechanisms. J Pathol. 3:289–99.
Hekim N, Cetin Z, Nikitaki Z, Cort A, Saygili EI (2015). Radiation triggering immune response and inflammation. Cancer Lett. 2:156–63.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Aisha alhadimaualidi, Hayat Ali Alshamly, Amina Bshaena (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
